Accelovance Nominated for TWO 2014 Vaccine Industry Excellence (ViE) Awards "Best Contract Research Organization" & "Best Clinical Trial Network and Site"
ROCKVILLE, Md., March 6, 2014 /PRNewswire-USNewswire/ -- Accelovance, a therapeutically focused clinical research organization (CRO), has been named a finalist for two Vaccine Industry Excellence (ViE) Awards, with nominations for "Best Contract Research Organization" and "Best Clinical Trial Network and Site."
This is the seventh consecutive year Accelovance has been honored as an award nominee at the World Vaccine Congress, winning for "Best Contract Research Organization" in 2009, 2010, and 2011, as well as receiving a "Highly Recommended" distinction in 2013.
"We're honored to be nominated for these two awards, which highlight the continued depth and breadth of our leadership and experience within the conduct of vaccine trials. Our dedication to serving the needs and advancing the research of Sponsors in this important therapeutic area continues to be validated by this global Conference distinction," commented Stephen J. Trevisan, Accelovance President and Chief Executive Officer.
Accelovance will be evaluated by an international panel for quality of services, performance, client satisfaction, Sponsor relationships, and the overall value brought to study Sponsors. Accelovance is well known within the industry for its experience in managing vaccine trials, for successful clinical oversight, patient enrollment and retention, and for providing full service solutions to Sponsors. Award winners will be announced at the 14th Annual World Vaccine Congress being held in Washington, D.C. March 24-26, 2014.
Accelovance is an award-winning, niche CRO focused primarily in vaccines, oncology, and general medicine. Accelovance operates four core service divisions; a full-service Contract Research Organization, Site Management Organization, Patient Recruitment, and Call Center that positively impact the advancement of clinical research. As a clinical services provider to the pharmaceutical and biotech industries, Accelovance offers comprehensive services including management and implementation of Phase I-IV clinical trials, patient recruitment/retention solutions, and a Clinical Call Center that can assist in recruitment, retention, and post-marketing surveillance.
Established in 2005 with a corporate mission to improve the quality and predictability in clinical research, Accelovance is a privately held company headquartered in Rockville, Maryland. Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise.
Press Contact: Michael Keens, VP Business Development